Sublingual immunotherapy: Focus on tablets

Annals of Allergy, Asthma and Immunology

Volumn 115, Issue 1, 2015, Pages 4-9

  Passalacqua, Giovanni ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GRASS POLLEN EXTRACT; PLACEBO; POLLEN EXTRACT; RAGWEED POLLEN EXTRACT; ALLERGEN; HOUSE DUST ALLERGEN; TABLET;

AGE; ASTHMA; AUTOIMMUNE DISEASE; BURNING MOUTH SYNDROME; COST CONTROL; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EAR PRURITUS; HUMAN; LIP DISEASE; LIP SWELLING; MOUTH EDEMA; NAUSEA; ORAL PARESTHESIA; ORAL PRURITUS; PHARYNGEAL EDEMA; PHARYNX DISEASE; PHLEUM PRATENSE; POLLEN ALLERGY; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; RAGWEED; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; RHINITIS; STOMACH PAIN; SUBLINGUAL IMMUNOTHERAPY; TABLET FORMULATION; THROAT IRRITATION; TONGUE SWELLING; TREATMENT DURATION; TREATMENT WITHDRAWAL; URTICARIA; ADULT; ADVERSE EFFECTS; ANAPHYLAXIS; CASE REPORT; CONJUNCTIVITIS, ALLERGIC; CONTRAINDICATIONS; DESENSITIZATION; DOUBLE BLIND PROCEDURE; ECONOMICS; EDEMA; GASTROINTESTINAL ABSORPTION; IMMUNOLOGY; MALE; MULTICENTER STUDY (TOPIC); PATIENT ATTITUDE; POACEAE; POLLEN; PRURITUS; RHINITIS, ALLERGIC, SEASONAL; SUBLINGUAL DRUG ADMINISTRATION; TABLET; TH2 CELL;

ADMINISTRATION, SUBLINGUAL; ADULT; ALLERGENS; AMBROSIA; ANAPHYLAXIS; ANTIGENS, DERMATOPHAGOIDES; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; EDEMA; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; ORAL MUCOSAL ABSORPTION; PATIENT ACCEPTANCE OF HEALTH CARE; POACEAE; POLLEN; PRURITUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, SEASONAL; TABLETS; TH2 CELLS;

EID: 84937468618     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2015.03.022     Document Type: Review

References (51)

1. G.W. Canonica, and G. Passalacqua Noninjection routes for immunotherapy J Allergy Clin Immunol 111 2003 437 448
2. H.H. Windom, and R.F. Lockey An update on the safety of specific immunotherapy Curr Opin Allergy Clin Immunol 8 2008 571 576
3. G. Passalacqua, M. Albano, L. Fregonese, and et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis Lancet 351 1998 629 632
4. G.K. Scadding, and J. Brostoff Low dose sublingual therapy in patients with allergic rhinitis due to dust mite Clin Allergy 16 1986 483 487
5. J. Bousquet, R. Lockey, and H.J. Malling World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases Allergy 53 Suppl 52 1998 3 15
6. J. Bousquet, N. Khaltaev, A.A. Cruz, and et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) Allergy 63 Suppl 86 2008 8 160
7. G.W. Canonica, J. Bousquet, T. Casale, and et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009 Allergy 64 Suppl 91 2009 1 59
8. G.W. Canonica, L. Cox, R. Pawankar, and et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update World Allergy Organ J 7 2014 6
9. C.A. Thompson Sublingual immunotherapy approved for grass pollen allergies Am J Health Syst Pharm 71 2014 770
10. FDA press release. FDA approves Ragwitek for short ragweed pollen allergies. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393820.htm. Published April 17, 2014.
11. S.R. Durham, W.H. Yang, M.R. Pedersen, and et al. Sublingual immunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis J Allergy Clin Immunol 117 2006 802 809
12. A. Didier, H.J. Malling, M. Worm, and et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis J Allergy Clin Immunol 120 2007 1338 1345
13. R. Dahl, A. Kapp, G. Colombo, and et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis J Allergy Clin Immunol 118 2006 434 440
14. M. Blaiss, J. Maloney, H. Nolte, S. Gawchik, R. Yao, and D.P. Skoner Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents J Allergy Clin Immunol 127 2011 64 71
15. H.S. Nelson, H. Nolte, P. Creticos, J. Maloney, J. Wu, and D.I. Bernstein Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults J Allergy Clin Immunol 127 2011 72 80
16. L.S. Cox, T.B. Casale, A.S. Nayak, and et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE J Allergy Clin Immunol 130 2012 1327 1334
17. P.S. Creticos, J. Maloney, D.I. Bernstein, and et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults J Allergy Clin Immunol 131 2013 1342 1349
18. H. Nolte, J. Hébert, G. Berman, and et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults Ann Allergy Asthma Immunol 110 2013 450 456
19. H. Mosbech, R. Deckelmann, F. de Blay, and et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial J Allergy Clin Immunol 134 2014 568 575
20. K.C. Bergmann, P. Demoly, M. Worm, and et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis J Allergy Clin Immunol 133 2014 1608 1614
21. J. Maloney, D.I. Bernstein, H. Nelson, and et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial Ann Allergy Asthma Immunol 112 2014 146 153
22. T.B. Casale, G.W. Canonica, J. Bousquet, and et al. Recommendations for appropriate sublingual immunotherapy clinical trials J Allergy Clin Immunol 124 2009 665 670
23. S.R. Durham, W. Emminger, A. Kapp, and et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial J Allergy Clin Immunol 129 2012 717 725
24. A. Didier, H.J. Malling, M. Worm, and et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis Clin Exp Allergy 43 2013 568 577
25. M. Marogna, I. Spadolini, A. Massolo, G.W. Canonica, and G. Passalacqua Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study J Allergy Clin Immunol 126 2010 969 975
26. L. Cox, D. Larenas Linnemann, H. Nolte, D. Weldon, I. Finegold, and H.S. Nelson Sublingual immunotherapy: a comprehensive review J Allergy Clin Immunol 117 2006 1021 1035
27. G. Passalacqua, C.E. Baena-Cagnani, J. Bousquet, and et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language J Allergy Clin Immunol 132 2013 93 98
28. M.A. Calderón, F.E. Simons, H.J. Malling, R.F. Lockey, P. Moingeon, and P. Demoly Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile Allergy 6 2012 302 311
29. K.C. Nadeau Immune mechanisms of sublingual immunotherapy Curr Allergy Asthma Rep 14 2014 473
30. C. Ozdemir, U.C. Kucuksezer, M. Akdis, and C.A. Akdis Under the skin or under the tongue: differences and similarities in mechanisms of sublingual and subcutaneous immunotherapy Immunotherapy 5 2013 1151 1158
31. L. Böhm, J. Maxeiner, H. Meyer-Martin, and et al. IL-10 and regulatory T cells cooperate in allergen-specific immunotherapy to ameliorate allergic asthma J Immunol 194 2015 887 897
32. H. Fujita, M.B. Soyka, M. Akdis, and C.A. Akdis Mechanisms of allergen-specific immunotherapy Clin Transl Allergy 2 2012 2
33. C. Lombardi, C. Incorvaia, M. Braga, G.W. Canonica, and G. Passalacqua Administration regimens for sublingual immunotherapy to pollen allergens: what do we know? Allergy 64 2009 849 854
34. G.B. Pajno, L. Caminiti, G. Crisafulli, and et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study Pediatr Allergy Immunol 22 2011 803 807
35. I. Stelmach, I. Kaluzińska-Parzyszek, J. Jerzynska, P. Stelmach, W. Stelmach, and P. Majak Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children Allergy 67 2012 312 320
36. A. Nakonechna, J. Hills, J. Moor, P. Dore, and M. Abuzakouk Grazax sublingual immunotherapy in pre-co-seasonal and continuous treatment regimens: is there a difference in clinical efficacy? Ann Allergy Asthma Immunol 114 2015 73 74
37. I. Stelmach, A. Sobocińska, P. Majak, K. Smejda, J. Jerzyńska, and W. Stelmach Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy Ann Allergy Asthma Immunol 109 2012 274 278
38. L. Cox, and L. Jacobsen Comparison of allergen immunotherapy practice patterns in the United States and Europe Ann Allergy Asthma Immunol 103 2009 451 459
39. C. Lombardi, S. Gargioni, M. Cottini, G.W. Canonica, and G. Passalacqua The safety of sublingual immunotherapy with one or more allergens in adults Allergy 63 2008 375 376
40. F. Agostinis, C. Foglia, M. Landi, and et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children Allergy 63 2008 1637 1639
41. G. Ciprandi, G. Melioli, and G. Passalacqua Canonica GW Immunotherapy in polysensitized patients: new chances for the allergists? Ann Allergy Asthma Immunol 109 2012 392 394
42. 2LEN consensus document on molecular-based allergy diagnostics World Allergy Organ J 6 2013 17
43. C.S. Henkin, and L. Cox Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol 14 2014 363 370
44. S.M. Ronborg, U.G. Svendsen, J.S. Micheelsen, and et al. Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis Clinicoecon Outcomes Res 4 2012 253 260
45. M.A. Calderon, T.B. Casale, H.S. Nelson, and P. Demoly An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies J Allergy Clin Immunol 132 2013 1322 1336
46. G. Passalacqua Specific immunotherapy: beyond the clinical scores Ann Allergy Asthma Immunol 107 2011 401 406
47. G. Passalacqua Specific immunotherapy in asthma: a comprehensive review J Asthma 51 2014 29 33
48. F. de Blay, P. Kuna, L. Prieto, and et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma - post hoc results from a randomised trial Respir Med 108 2014 1430 1437
49. P.J. Bousquet, M.A. Calderon, P. Demoly, and et al. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article J Allergy Clin Immunol 127 2011 49 56
50. S. Elenburg, and M.S. Blaiss Current status of sublingual immunotherapy in the United States World Allergy Organ J 7 2014 24
51. H.S. Nelson Sublingual immunotherapy: the U.S. experience Curr Opin Allergy Clin Immunol 13 2013 663 668